A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
You may also be interested in...
Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far
Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.